NEXGEL Q1 revenue $1.27M (+104% YoY); net loss $905K vs $807K YoY

NEXGEL, INC.

2024-Q1 EPS reported -$0.14 revenue$1,266,000

Revenue increased 104% to $1.27M, driven by contract manufacturing (+58%) and branded products (+178%).
Gross profit turned positive to $277K from a loss of $57K YoY; gross margin 21.9% vs negative 9.2%.
Net loss widened to $905K from $807K; SG&A up 43.8% to $1.1M on higher advertising and consulting costs.
Cash balance $2.4M as of March 31, 2024, including ~$1M insider-led registered direct offering.
Capacity expansion in Texas nearly complete; product launches with Abbvie and European market entry expected.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEXGEL, INC. reported the quarter ended March 31, 2024 results: revenue $1.27 million, net income $905,000.

Period: the quarter ended March 31, 2024
Revenue: $1.27 million
Net income: $905,000
Result: reported results

Exact text from the filing

as shall be expressly set forth by specific reference in such a filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year LANGHORNE, Pa. – May 13, 2024 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle,

View on SEC.gov

1443 earnings releases filed in the last 30 days. Browse all earnings releases →

NEXGEL, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-018955

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.